Dentons has advised Ciklum on its acquisition of Czech-based software development company CN Group from Genesis Capital. Havel & Partners advised Genesis Capital on the deal.
On 31 January 2022, the “new” Regulation (EU) No. 536/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use and repealing Directive 2001/20/EC (the “Regulation“) will enter into force. After several delays (the launch was originally planned for 2015), the European Medicines Agency (the “EMA”) has confirmed to the Commission that the EU portal and the EU database, which were a prerequisite for the launch, are now fully functioning. At the same time, the EMA confirmed that the EU portal and database will be put into operation on 31 January 2022. As of this date, the Regulation will become fully applicable in all EU Member States.
Havel & Partners' Partner Frantisek Korbel, acting as a legal representative for the Ceske Radiokomunikace a.s. telecommunications company, has successfully appealed a Czech Supreme Court resolution to the Czech Constitutional Court in a dispute over the removal of the Petrov TV translator station from property owned by the defendant.
Havel & Partners has advised Sebre, Havel & Partners' Managing Partner Jaroslav Havel, and Sebre Managing Director Jan Kubicek, on the joint acquisition of a 50% shareholding in SousedeCZ, a company operating an online platform for digital communication of homeowner associations in residential buildings, from entrepreneurs Tomas Holomoucky and Tomas Sikora.